Filing Flows › ClearPoint Neuro (CLPT) › R&D spending
ClearPoint Neuro (CLPT) R&D spending by quarter
ClearPoint Neuro's R&D spending was $4.0M in Q3 2026 (third quarter 2026), -13% from Q2 2026. Over the last 7 quarters it ranged from $3.2M (Q4 2025) to $4.6M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $4.0M | -13% | +16% |
| Q2 2026 | $4.6M | +2% | +21% |
| Q1 2026 | $4.5M | +40% | +34% |
| Q4 2025 | $3.2M | -6% | — |
| Q3 2025 | $3.5M | -10% | — |
| Q2 2025 | $3.8M | +13% | — |
| Q1 2025 | $3.4M | — | — |
Q3 2026 at a glance
ClearPoint Neuro, Q3 2026: revenue $12.1M (+36% year over year), operating margin -52.4%, net loss $7.5M, operating cash flow −$5.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is ClearPoint Neuro's R&D spending?
ClearPoint Neuro's R&D spending was $4.0M in Q3 2026 (third quarter 2026), -13% from Q2 2026.
How has ClearPoint Neuro's R&D spending changed?
Over the last 7 quarters it ranged from $3.2M (Q4 2025) to $4.6M (Q2 2026).